STOCK TITAN
  1. Home
  2. Sec-filings
  3. HAE
  4. [Form 4] HAEMONETICS CORP Insider Trading Activity

Haemonetics (NYSE: HAE) director receives 2,538 RSUs equity award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Haemonetics Corp director Lloyd Emerson Johnson reported an equity compensation award of 2,538 shares of common stock in the form of restricted stock units (RSUs) on 2026-07-24. The RSUs vest 100% on the first anniversary of the grant date, with each RSU converting into one share of common stock when vested.

After this grant, Johnson’s directly held common stock position was reported as 15,471 shares.

Positive

  • None.

Negative

  • None.
Insider Johnson Lloyd Emerson
Role Director
Type Security Shares Price Value
Grant/Award Common Stock F1, F2 2,538 -- --
Holdings After Transaction: Common Stock — 15,471 shares (Direct)
Footnotes (2)
  1. F1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
  2. F2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
RSUs granted 2,538 shares Restricted stock units granted on 2026-07-24
Shares following transaction 15,471 shares Common stock reported as beneficially owned after the award
RSU conversion ratio 1 share per RSU Each RSU represents a contingent right to receive one share upon vesting
restricted stock units ("RSUs") financial
"The securities awarded are in the form of restricted stock units ("RSUs")"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
contingent right financial
"Each RSU represents a contingent right to receive one (1) share"
Long-Term Incentive Compensation Plan financial
"pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transaction did Haemonetics (HAE) director Lloyd Emerson Johnson report?
Lloyd Emerson Johnson reported an equity award of 2,538 RSUs tied to Haemonetics common stock. The RSUs vest 100% one year after the 2026-07-24 grant, and his holdings after the award were 15,471 shares.

How many Haemonetics (HAE) shares did Lloyd Emerson Johnson hold after this Form 4 transaction?
Following the reported grant, Lloyd Emerson Johnson’s beneficial ownership was 15,471 shares of Haemonetics common stock. This figure reflects his direct holdings after receiving the 2,538-share RSU award.

What type of securities were granted to Lloyd Emerson Johnson in Haemonetics (HAE)?
He received restricted stock units (RSUs) linked to Haemonetics common stock. Each RSU is a contingent right to one share of common stock that is delivered only when the RSUs vest.

What is the vesting schedule for Lloyd Emerson Johnson’s Haemonetics (HAE) RSUs?
The 2,538 RSUs granted to Lloyd Emerson Johnson vest 100% on the first anniversary of the 2026-07-24 grant date. Shares of common stock are issued only after this vesting condition is met.

Under what plan were the RSUs granted to Haemonetics (HAE) director Lloyd Emerson Johnson?
The RSUs were issued under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. This plan governs equity-based compensation, including the 2,538 RSUs reported in the transaction.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Johnson Lloyd Emerson
(Last)(First)(Middle)
125 SUMMER STREET
(Street)
BOSTON MASSACHUSETTS 02110
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/24/2026A2,538(1)A(2)15,471D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
/s/ Thomas V. Powers, attorney-in-fact for Mr. Johnson07/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR